ECSP18038014A - Bloqueador del canal de sodio - Google Patents
Bloqueador del canal de sodioInfo
- Publication number
- ECSP18038014A ECSP18038014A ECIEPI201838014A ECPI201838014A ECSP18038014A EC SP18038014 A ECSP18038014 A EC SP18038014A EC IEPI201838014 A ECIEPI201838014 A EC IEPI201838014A EC PI201838014 A ECPI201838014 A EC PI201838014A EC SP18038014 A ECSP18038014 A EC SP18038014A
- Authority
- EC
- Ecuador
- Prior art keywords
- sodium channel
- channel blocker
- present
- prevention
- pharmaceutically acceptable
- Prior art date
Links
- 239000003195 sodium channel blocking agent Substances 0.000 title abstract 2
- 229940125794 sodium channel blocker Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a un compuesto representado por la Fórmula Química, o una sal farmacéuticamente aceptable del mismo. El compuesto según la presente invención puede usarse de manera útil para la prevención o el tratamiento de enfermedades relacionadas con bloqueantes de canales de sodio.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150159637 | 2015-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP18038014A true ECSP18038014A (es) | 2018-05-31 |
Family
ID=58695815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201838014A ECSP18038014A (es) | 2015-11-13 | 2018-05-18 | Bloqueador del canal de sodio |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10227338B2 (es) |
| EP (1) | EP3375782B1 (es) |
| JP (1) | JP6559894B2 (es) |
| KR (1) | KR102245930B1 (es) |
| CN (1) | CN108349963B (es) |
| AU (1) | AU2016351526B2 (es) |
| BR (1) | BR112018009754B1 (es) |
| CA (1) | CA3003119C (es) |
| CL (1) | CL2018001281A1 (es) |
| CO (1) | CO2018005064A2 (es) |
| EC (1) | ECSP18038014A (es) |
| ES (1) | ES2821962T3 (es) |
| HR (1) | HRP20201695T1 (es) |
| HU (1) | HUE052569T2 (es) |
| MA (1) | MA43231B1 (es) |
| MX (1) | MX376469B (es) |
| MY (1) | MY194015A (es) |
| NZ (1) | NZ742069A (es) |
| PE (1) | PE20181301A1 (es) |
| PH (1) | PH12018500999A1 (es) |
| PL (1) | PL3375782T3 (es) |
| PT (1) | PT3375782T (es) |
| RS (1) | RS60927B1 (es) |
| RU (1) | RU2705578C1 (es) |
| SA (1) | SA518391540B1 (es) |
| SG (1) | SG11201803867TA (es) |
| SI (1) | SI3375782T1 (es) |
| TN (1) | TN2018000157A1 (es) |
| WO (1) | WO2017082688A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201903348UA (en) * | 2016-10-17 | 2019-05-30 | Genentech Inc | Therapeutic compounds and methods of use thereof |
| TW202003490A (zh) * | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| WO2020052509A1 (zh) * | 2018-09-10 | 2020-03-19 | 成都康弘药业集团股份有限公司 | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 |
| CN112759559B (zh) * | 2019-11-06 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5591761A (en) * | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5464853A (en) | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| NZ528120A (en) * | 2001-03-12 | 2006-05-26 | Ono Pharmaceutical Co | N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same |
| JP2006290791A (ja) * | 2005-04-11 | 2006-10-26 | Astellas Pharma Inc | アゾール置換スルホニルベンゼン誘導体 |
| JP2008542219A (ja) * | 2005-05-25 | 2008-11-27 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | 疼痛処置法 |
| CA2652669A1 (en) | 2006-06-09 | 2007-12-21 | Merck & Co., Inc. | Benzazepinones as sodium channel blockers |
| US9422235B2 (en) * | 2006-12-19 | 2016-08-23 | Pharmos Corporation | Sulfonamide derivatives with therapeutic indications |
| SA08290245B1 (ar) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| JP2008290791A (ja) * | 2007-05-22 | 2008-12-04 | Funai Electric Co Ltd | 画像形成装置 |
| EP2173743A2 (en) * | 2007-07-13 | 2010-04-14 | Icagen, Inc. | Sodium channel inhibitors |
| HUE025013T2 (hu) * | 2009-01-12 | 2016-04-28 | Pfizer Ltd | Szulfonamid-származékok |
| CA2801032A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
| JP6014155B2 (ja) * | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| EP2788332A1 (en) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| ES2593533T3 (es) | 2011-12-15 | 2016-12-09 | Pfizer Limited | Derivados de sulfonamida |
| WO2013093688A1 (en) | 2011-12-19 | 2013-06-27 | Pfizer Limited | Sulfonamide derivatives and use thereof as vgsc inhibitors |
| BR112014029161A2 (pt) | 2012-05-22 | 2017-06-27 | Genentech Inc | benzamidas n-substituídas e seu uso no tratamento de dor |
| WO2014061970A1 (en) * | 2012-10-15 | 2014-04-24 | Daewoong Pharmaceutical Co., Ltd. | Sodium channel blockers, preparation method thereof and use thereof |
| WO2015130957A1 (en) * | 2014-02-27 | 2015-09-03 | Zalicus Pharmaceuticals, Ltd. | Heterocyclic inhibitors of the sodium channel |
-
2016
- 2016-11-11 EP EP16864614.9A patent/EP3375782B1/en active Active
- 2016-11-11 KR KR1020160150511A patent/KR102245930B1/ko active Active
- 2016-11-11 US US15/771,775 patent/US10227338B2/en active Active
- 2016-11-11 RU RU2018119954A patent/RU2705578C1/ru active
- 2016-11-11 JP JP2018524451A patent/JP6559894B2/ja active Active
- 2016-11-11 BR BR112018009754-3A patent/BR112018009754B1/pt active IP Right Grant
- 2016-11-11 PT PT168646149T patent/PT3375782T/pt unknown
- 2016-11-11 CA CA3003119A patent/CA3003119C/en active Active
- 2016-11-11 SG SG11201803867TA patent/SG11201803867TA/en unknown
- 2016-11-11 CN CN201680066269.7A patent/CN108349963B/zh active Active
- 2016-11-11 MX MX2018005940A patent/MX376469B/es active IP Right Grant
- 2016-11-11 PL PL16864614.9T patent/PL3375782T3/pl unknown
- 2016-11-11 AU AU2016351526A patent/AU2016351526B2/en active Active
- 2016-11-11 PE PE2018000765A patent/PE20181301A1/es unknown
- 2016-11-11 NZ NZ742069A patent/NZ742069A/en unknown
- 2016-11-11 TN TNP/2018/000157A patent/TN2018000157A1/en unknown
- 2016-11-11 MA MA43231A patent/MA43231B1/fr unknown
- 2016-11-11 HR HRP20201695TT patent/HRP20201695T1/hr unknown
- 2016-11-11 WO PCT/KR2016/013029 patent/WO2017082688A1/ko not_active Ceased
- 2016-11-11 ES ES16864614T patent/ES2821962T3/es active Active
- 2016-11-11 MY MYPI2018000662A patent/MY194015A/en unknown
- 2016-11-11 SI SI201630902T patent/SI3375782T1/sl unknown
- 2016-11-11 HU HUE16864614A patent/HUE052569T2/hu unknown
- 2016-11-11 RS RS20201235A patent/RS60927B1/sr unknown
-
2018
- 2018-05-08 PH PH12018500999A patent/PH12018500999A1/en unknown
- 2018-05-09 SA SA518391540A patent/SA518391540B1/ar unknown
- 2018-05-10 CL CL2018001281A patent/CL2018001281A1/es unknown
- 2018-05-11 CO CONC2018/0005064A patent/CO2018005064A2/es unknown
- 2018-05-18 EC ECIEPI201838014A patent/ECSP18038014A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020014586A2 (es) | Compuestos | |
| DOP2020000112A (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
| MX380394B (es) | Compuesto novedoso de bifenilo o una sal del mismo. | |
| MX2022005160A (es) | Oxisteroles y metodos de uso de los mismos. | |
| CO2019004034A2 (es) | Compuesto de piridina | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| DOP2015000201A (es) | Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos | |
| MX2016011160A (es) | Tratamiento de afecciones asociadas con la hiperinsulinemia. | |
| CL2018002583A1 (es) | Derivado de morfolina | |
| CR20150325A (es) | Compuestos trcíclicos para inhibir el canal cftr | |
| AR095097A1 (es) | Compuestos de fenoxietoxi | |
| AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
| MX2019002369A (es) | Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial. | |
| CO2018005064A2 (es) | Bloqueador del canal de sodio | |
| ECSP18009366A (es) | Antagonistas del receptor de cgrp | |
| SV2019005838A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| MX2017006110A (es) | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. | |
| AR110770A1 (es) | Moduladores del canal de potasio | |
| PH12017501404A1 (en) | Diaza-benzofluoranthrene compounds | |
| MX2022006984A (es) | Procesos e intermediario para la preparacion de oxetan-2-ilmetanamina. | |
| MX2022000651A (es) | Proceso mejorado para preparar ozanimod. | |
| AR115865A2 (es) | Compuestos terapéuticos | |
| MX2018007796A (es) | Compuestos de fenilimidazol. | |
| UY36096A (es) | Inhibir el canal de iones del potencial del receptor transitorio a1 |